Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

654085.pdf (1.95 MB)

Document type

Article

Version

Published version

Publication date

2015-09

Publication license

cc-by-nc-nd (c) American Diabetes Association, 2015
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/135123

Growth hormone inhibits hepatic de novo lipogenesis in adult mice

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.2337/db15-0370

Abstract

Patients with nonalcoholic fatty liver disease (NAFLD) are reported to have low growth hormone (GH) production and/or hepatic GH resistance. GH replacement can resolve the fatty liver condition in diet-induced obese rodents and in GH-deficient patients. However, it remains to be determined whether this inhibitory action of GH is due to direct regulation of hepatic lipid metabolism. Therefore, an adult-onset, hepatocyte-specific, GH receptor (GHR) knockdown (aLivGHRkd) mouse was developed to model hepatic GH resistance in humans that may occur after sexual maturation. Just 7 days after aLivGHRkd, hepatic de novo lipogenesis (DNL) was increased in male and female chow-fed mice, compared with GHR-intact littermate controls. However, hepatosteatosis developed only in male and ovariectomized female aLivGHRkd mice. The increase in DNL observed in aLivGHRkd mice was not associated with hyperactivation of the pathway by which insulin is classically considered to regulate DNL. However, glucokinase mRNA and protein levels as well as fructose-2,6-bisphosphate levels were increased in aLivGHRkd mice, suggesting that enhanced glycolysis drives DNL in the GH-resistant liver. These results demonstrate that hepatic GH actions normally serve to inhibit DNL, where loss of this inhibitory signal may explain, in part, the inappropriate increase in hepatic DNL observed in NAFLD patients.

Subject

Glucocinasa, Somatotropina, Metabolisme, Malalties del fetge, Genètica, RNA, Ratolins (Animals de laboratori)

Subject (English)

Glucokinase, Somatotropin, Metabolism, Liver diseases, Genetics, RNA, Mice (Laboratory animals)

Citation

Collections

Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

CORDOBA-CHACON, Jose, et al. Growth hormone inhibits hepatic de novo lipogenesis in adult mice. Diabetes. 2015. Vol. 64, num. 9, pags. 3093-3103. ISSN 0012-1797. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/135123

Export metadata

JSON - METS

Share record